Puma Biotechnology, Inc.PBYINASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -18.15% | +5.12% | +11.37% | -32.36% | +27.80% |
| Gross Profit Growth | -5.64% | +7.30% | +10.19% | -17.77% | +15.82% |
| EBITDA Growth | -3.34% | +396.09% | +405.64% | -49.39% | +50.03% |
| Operating Income Growth | -9.68% | +0.00% | +0.00% | -56.64% | +27.95% |
| Net Income Growth | +57.36% | +0.00% | +0.00% | -56.47% | -30.59% |
| EPS Growth | +50.00% | +0.00% | +0.00% | -56.10% | -30.77% |
| EPS Diluted Growth | +50.00% | +0.00% | +0.00% | -58.54% | -33.33% |
| Weighted Average Shares Growth | +3.14% | +2.92% | +2.92% | +2.72% | +2.53% |
| Weighted Average Shares Diluted Growth | +2.85% | +3.56% | +3.84% | +3.57% | +4.28% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +49.28% | -67.88% | +1271.18% | -12.22% | -7.61% |
| Free Cash Flow Growth | +49.77% | -68.42% | +1296.43% | -12.30% | -7.29% |
| Receivables Growth | -33.98% | +2.39% | -7.81% | -38.57% | +67.61% |
| Inventory Growth | +23.22% | +23.25% | -5.06% | +254.51% | -100.00% |
| Asset Growth | -7.46% | -8.39% | -4.92% | -8.09% | +1.39% |
| Book Value per Share Growth | +67.13% | +85.07% | +109.76% | +57.86% | +37.99% |
| Debt Growth | -33.55% | -44.27% | -50.06% | -52.47% | -61.47% |
| R&D Expense Growth | +17.84% | +2.03% | +13.35% | +26.82% | +10.75% |
| SG&A Expenses Growth | -15.68% | -20.04% | -26.28% | -0.30% | +8.11% |